Go Pro
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel Free ONCY Stock Alerts

Oncolytics Biotech (ONCY) Financials

Oncolytics Biotech logo
$0.92 +0.13 (+16.12%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$0.91 -0.01 (-0.98%)
As of 05:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Oncolytics Biotech

Annual Income Statements for Oncolytics Biotech

This table shows Oncolytics Biotech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.57 -11 -13 -12 -26 -18 -21 -18 -21 -23 -29
Consolidated Net Income / (Loss)		 -9.92 -11 -12 -12 -26 -18 -21 -18 -21 -23 -29
Net Income / (Loss) Continuing Operations		 -9.92 -11 -12 -12 -26 -18 -21 -18 -21 -23 -29
Total Pre-Tax Income 		-9.92 -11 -12 -12 -26 -18 -21 -18 -21 -23 -29
Total Operating Income		 -10 -11 -12 -13 -16 -20 -21 -20 -26 -26 -29
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 10 11 12 13 16 20 21 20 26 26 29
Selling, General & Admin Expense		 - - - - - - 10 8.49 12 10 15
Research & Development Expense		 6.22 7.27 7.46 7.35 8.34 10 10 11 13 15 13
Total Other Income / (Expense), net		 0.14 0.12 0.10 0.57 -9.82 2.32 -0.02 1.61 4.65 2.84 0.05
Interest & Investment Income		 - 0.12 - - - - - - - 0.98 -0.00
Other Income / (Expense), net		 - - 0.00 0.45 -9.96 2.22 -0.09 1.22 3.64 1.87 0.05
Income Tax Expense		 0.00 0.01 0.11 0.40 0.00 0.00 0.04 0.06 0.07 0.10 0.08
Basic Earnings per Share		 ($0.12) ($1.20) ($1.12) ($1.06) ($1.50) ($0.56) ($0.49) ($0.32) ($0.31) ($0.30) ($0.30)
Weighted Average Basic Shares Outstanding		 112.61M 12.62M 13.94M 16.02M 22.14M 40.34M 53.51M 58.03M 67.62M 76.48M 95.86M
Diluted Earnings per Share		 ($0.12) ($1.20) ($1.12) ($1.06) ($1.50) ($0.56) ($0.49) ($0.32) ($0.31) ($0.30) ($0.30)
Weighted Average Diluted Shares Outstanding		 112.61M 12.62M 13.94M 16.02M 22.14M 40.34M 53.51M 58.03M 67.62M 76.48M 95.86M
Weighted Average Basic & Diluted Shares Outstanding		 - - 141.81M 17.40M 32.20M 92.33M 55.04M 61.33M 74.42M 80.02M 116.13M

Quarterly Income Statements for Oncolytics Biotech

This table shows Oncolytics Biotech's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q1 2026
Period end date 3/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.71 -9.24
Consolidated Net Income / (Loss)		 -4.71 -9.24
Net Income / (Loss) Continuing Operations		 -4.71 -9.21
Total Pre-Tax Income 		-4.71 -9.24
Total Operating Income		 -5.02 -9.28
Total Gross Profit		 0.00 0.00
Total Revenue		 0.00 0.00
Total Cost of Revenue		 0.00 0.00
Total Operating Expenses		 5.02 9.28
Selling, General & Admin Expense		 2.22 4.73
Research & Development Expense		 2.80 4.55
Total Other Income / (Expense), net		 0.31 0.04
Interest & Investment Income		 0.12 0.04
Other Income / (Expense), net		 0.19 -0.01
Other Gains / (Losses), net		 - 0.04
Basic Earnings per Share		 ($0.06) ($0.08)
Weighted Average Basic Shares Outstanding		 84.63M 112.29M
Diluted Earnings per Share		 ($0.06) ($0.08)
Weighted Average Diluted Shares Outstanding		 84.63M 112.29M
Weighted Average Basic & Diluted Shares Outstanding		 - 119.35M

Annual Cash Flow Statements for Oncolytics Biotech

This table details how cash moves in and out of Oncolytics Biotech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 6.14 -8.61 -0.08 0.93 0.85 14 8.06 -23 18 -15 -5.88
Net Cash From Operating Activities		 11 9.29 -12 -8.73 -15 -17 -18 -17 -23 -20 -20
Net Cash From Continuing Operating Activities		 -11 -9.71 -12 -8.73 -15 -17 -18 -32 -23 -20 -20
Net Income / (Loss) Continuing Operations		 -9.92 -11 -12 -12 -26 -18 -21 -18 -21 -23 -29
Consolidated Net Income / (Loss)		 - - -12 -12 -26 -18 -21 -18 -21 -23 -29
Depreciation Expense		 0.13 - 0.07 0.07 0.37 0.35 0.35 0.29 0.06 0.09 0.07
Non-Cash Adjustments To Reconcile Net Income		 -1.39 1.56 0.50 3.67 9.81 -0.06 2.62 -14 -2.22 1.24 5.72
Changes in Operating Assets and Liabilities, net		 - - - - - - - - - 1.59 2.86
Net Cash From Investing Activities		 -0.10 -0.04 1.58 -0.08 -0.01 -0.02 -0.22 -15 15 -0.17 -0.01
Net Cash From Continuing Investing Activities		 -0.10 -0.04 1.58 -0.08 -0.01 -0.02 -0.22 -0.04 15 -0.17 -0.01
Purchase of Property, Plant & Equipment		 -0.08 -0.02 -0.08 -0.08 -0.01 -0.02 -0.22 -0.04 -0.01 -0.17 -0.01
Net Cash From Financing Activities		 17 0.71 10 9.75 16 31 26 9.02 24 5.03 14
Net Cash From Continuing Financing Activities		 17 0.71 10 9.75 17 31 26 9.02 24 5.03 14
Repayment of Debt		 - - - - - - - - - 0.00 -0.03
Issuance of Common Equity		 14 0.71 9.91 9.65 17 31 26 9.29 24 4.98 14
Other Financing Activities, net		 0.00 0.00 0.27 0.09 0.00 -0.17 -0.10 -0.27 0.28 0.05 0.03
Effect of Exchange Rate Changes		 - - - - - - - - - -0.29 0.12

Quarterly Cash Flow Statements for Oncolytics Biotech

This table details how cash moves in and out of Oncolytics Biotech's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q1 2026
Period end date 3/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -0.43 0.29
Net Cash From Operating Activities		 -4.73 -7.29
Net Cash From Continuing Operating Activities		 -4.73 -7.29
Net Income / (Loss) Continuing Operations		 -4.71 -9.24
Consolidated Net Income / (Loss)		 -4.71 -9.24
Depreciation Expense		 0.02 0.02
Non-Cash Adjustments To Reconcile Net Income		 0.64 3.04
Changes in Operating Assets and Liabilities, net		 -0.68 -1.11
Net Cash From Investing Activities		 -0.00 -0.01
Net Cash From Continuing Investing Activities		 -0.00 -0.01
Purchase of Property, Plant & Equipment		 -0.00 -0.01
Net Cash From Financing Activities		 4.18 7.61
Net Cash From Continuing Financing Activities		 4.18 7.61
Issuance of Common Equity		 4.18 7.61
Other Net Changes in Cash		 0.12 -0.02

Annual Balance Sheets for Oncolytics Biotech

This table presents Oncolytics Biotech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 11 14 11 15 27 36 28 29 13 7.58
Total Current Assets		 11 14 11 15 26 35 26 29 12 6.84
Cash & Equivalents		 8.96 9.41 10 11 24 32 8.62 26 11 5.20
Accounts Receivable		 0.04 0.03 0.04 1.59 0.07 0.68 0.39 0.01 0.05 0.57
Prepaid Expenses		 0.19 0.93 0.51 2.09 1.90 - 2.24 2.46 1.31 1.07
Plant, Property, & Equipment, net		 0.24 0.26 0.30 0.23 0.19 0.31 0.26 0.21 0.29 0.23
Total Noncurrent Assets		 0.00 0.00 0.00 0.33 0.29 0.46 0.22 0.28 0.70 0.51
Other Noncurrent Operating Assets		 - - 0.00 0.33 0.29 0.46 0.22 0.28 0.70 0.51
Total Liabilities & Shareholders' Equity		 11 14 11 15 27 36 28 29 13 7.58
Total Liabilities		 3.03 7.84 6.35 15 7.52 7.66 8.00 8.53 10 11
Total Current Liabilities		 3.03 4.16 2.06 9.92 2.12 2.11 2.92 3.21 4.89 6.10
Accounts Payable		 3.03 2.93 1.34 2.45 1.41 1.56 2.70 2.71 0.76 3.50
Accrued Expenses		 - - - - - - - - 2.57 2.33
Other Current Liabilities		 0.00 1.23 0.72 7.47 0.71 0.55 0.22 0.50 1.56 0.27
Total Noncurrent Liabilities		 0.00 3.68 4.29 5.32 5.40 5.55 5.09 5.32 5.24 5.28
Noncurrent Deferred Revenue		 - - - - - - - - 4.68 4.91
Noncurrent Employee Benefit Liabilities		 - - - - - - - - - 0.00
Other Noncurrent Operating Liabilities		 0.00 3.68 4.29 5.19 5.28 5.27 5.09 5.32 0.56 0.37
Commitments & Contingencies		 - - - - - - - - 0.00 0.00
Total Equity & Noncontrolling Interests		 7.95 6.58 4.54 -0.08 19 28 20 21 3.30 -3.80
Total Preferred & Common Equity		 7.95 6.58 4.54 -0.08 19 28 20 21 3.30 -3.80
Total Common Equity		 7.95 6.58 4.54 -0.08 19 28 20 21 3.30 -3.80
Common Stock		 195 216 209 240 280 306 328 358 398 419
Retained Earnings		 -207 -234 -228 -266 -288 -308 -309 -338 -401 -429
Accumulated Other Comprehensive Income / (Loss)		 0.41 0.30 0.45 0.36 0.31 0.30 0.49 0.41 6.36 6.23

Quarterly Balance Sheets for Oncolytics Biotech

This table presents Oncolytics Biotech's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2026
Period end date 3/31/2026
Total Assets		 8.16
Total Current Assets		 7.49
Cash & Equivalents		 5.49
Accounts Receivable		 0.96
Prepaid Expenses		 1.03
Plant, Property, & Equipment, net		 0.22
Total Noncurrent Assets		 0.46
Other Noncurrent Operating Assets		 0.46
Total Liabilities & Shareholders' Equity		 8.16
Total Liabilities		 13
Total Current Liabilities		 5.42
Accounts Payable		 2.68
Accrued Expenses		 2.58
Other Current Liabilities		 0.17
Total Noncurrent Liabilities		 7.87
Noncurrent Deferred Revenue		 4.91
Noncurrent Employee Benefit Liabilities		 2.62
Other Noncurrent Operating Liabilities		 0.34
Commitments & Contingencies		 0.00
Total Equity & Noncontrolling Interests		 -5.13
Total Preferred & Common Equity		 -5.13
Total Common Equity		 -5.13
Common Stock		 427
Retained Earnings		 -439
Accumulated Other Comprehensive Income / (Loss)		 6.23

Annual Metrics And Ratios for Oncolytics Biotech

This table displays calculated financial ratios and metrics derived from Oncolytics Biotech's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 141,805,722.00 17,399,749.00 32,198,453.00 46,166,980.00 55,043,789.00 61,327,914.00 74,423,960.00 80,020,131.00 80,020,131.00
DEI Adjusted Shares Outstanding		 0.00 0.00 14,926,918.00 17,399,749.00 32,198,453.00 46,166,980.00 55,043,789.00 61,327,914.00 74,423,960.00 80,020,131.00 80,020,131.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.84 -0.71 -0.80 -0.38 -0.37 -0.30 -0.28 -0.28 -0.36
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -14.59% -8.33% 1.58% -108.43% 31.25% -16.59% 9.28% -19.03% -7.75% -21.29%
EBIT Growth		 0.00% -13.10% -8.96% 1.54% -110.20% 30.89% -16.29% 9.43% -17.51% -7.84% -21.14%
NOPAT Growth		 0.00% -13.10% -8.96% -2.06% -24.07% -27.09% -2.88% 3.10% -28.64% 0.21% -12.46%
Net Income Growth		 0.00% -13.55% -10.15% -0.60% -104.47% 30.89% -16.69% 10.85% -14.54% -8.43% -26.17%
EPS Growth		 0.00% -900.00% 6.67% 5.36% -41.51% 62.67% 12.50% 35.14% 2.27% 3.41% 0.00%
Operating Cash Flow Growth		 0.00% -14.58% -227.45% 26.19% -75.63% -12.76% -1.49% 1.70% -34.32% 14.23% -1.15%
Free Cash Flow Firm Growth		 0.00% 0.00% -55.45% 26.50% 8.90% -252.89% 32.64% -124.66% 92.94% -637.51% -20.57%
Invested Capital Growth		 0.00% 0.00% -10.48% -94.80% -97.46% 54.42% -19.84% 272.42% -154.43% -39.78% -15.68%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.02% 100.06% 100.91% 103.32% 100.00% 100.00% 100.19% 100.34% 100.35% 100.42% 100.28%
Interest Burden Percent		 98.58% 98.93% 99.17% 98.96% 99.46% 99.47% 99.62% 97.91% 95.42% 95.88% 100.01%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -141.63% -170.73% -224.48% -1,145.56% -182.62% -86.40% -76.73% -103.90% -188.57% 11,480.64%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -294.19% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -141.63% -170.73% -224.48% -1,145.56% -182.62% -86.40% -76.73% -103.90% -188.57% 11,480.64%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -141.63% -188.52% -275.00% 0.00% -90.92% -72.87% -93.71% -100.69% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.04 -7.97 -8.68 -8.86 -11 -14 -14 -14 -18 -18 -20
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -62.79% -37.45% -37.28% -139.66% -20.90% -21.23% -20.33% -17.34% -26.19% -106.28%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -71.11% -85.82% -542.13% 529.28%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -10 -11 -12 -12 -26 -18 -21 -19 -22 -24 -29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.93 -11 -12 -12 -25 -17 -20 -18 -22 -24 -29
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 5.95 0.00 3.95 2.27 4.58 3.97 20.62 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 5.95 0.00 3.95 2.27 4.58 3.97 20.62 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7.93 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 -1.54 0.01 0.01 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 -1.54 0.01 0.01 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.32 -1.37 -1.75 -4.67 -1.82 -1.23 -0.91 -0.88 -1.55 32.50
Leverage Ratio		 0.00 1.38 1.75 2.28 5.84 2.18 1.32 1.33 1.41 1.77 -41.92
Compound Leverage Factor		 0.00 1.37 1.73 2.25 5.81 2.17 1.31 1.30 1.34 1.70 -41.93
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 284.32% 0.62% 0.99% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 284.32% 0.62% 0.99% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 100.00% -184.32% 99.39% 99.01% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.01 -0.01 -0.01 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.43 1.40 1.58 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.01 -0.01 -0.01 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.01 -0.01 -0.02 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.98 1.74 2.23 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.01 -0.01 -0.02 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 -29.54 -26.50 -9.94 -7.77 -10.17 -11.67 -42.92 -87.98
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 3.55 3.41 5.13 1.47 12.45 16.69 9.05 9.01 2.55 1.12
Quick Ratio		 0.00 3.48 3.18 4.89 1.26 11.56 15.66 3.09 8.24 2.28 0.95
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -5.41 -8.41 -6.18 -5.63 -20 -13 -30 -2.12 -16 -19
Operating Cash Flow to CapEx		 13,886.61% 53,035.12% -14,079.55% -11,092.06% -182,545.67% -76,097.66% -7,843.70% -42,464.05% -382,555.29% -11,427.01% -335,200.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -2.56 -2.82 -5.50 -11 -4.95 -5.93 10 -5.57 -7.78 -9.00
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -2.56 -0.27 -2.68 -5.36 5.91 -0.98 16 -16 -2.21 -1.22
Enterprise Value (EV)		 0.00 0.00 0.00 17 72 52 32 81 56 57 65
Market Capitalization		 0.00 0.00 0.00 27 83 77 64 90 83 68 70
Book Value per Share		 $0.00 $0.63 $0.47 $0.03 $0.00 $0.60 $0.61 $0.36 $0.34 $0.04 ($0.05)
Tangible Book Value per Share		 $0.00 $0.63 $0.47 $0.03 $0.00 $0.60 $0.61 $0.36 $0.34 $0.04 ($0.05)
Total Capital		 0.00 7.95 6.58 4.54 0.05 20 29 20 21 3.30 -3.80
Total Debt		 0.00 0.00 0.00 0.00 0.13 0.12 0.28 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.13 0.12 0.28 0.00 0.00 0.00 0.00
Net Debt		 0.00 -11 -9.41 -10 -11 -24 -32 -8.62 -26 -11 -5.20
Capital Expenditures (CapEx)		 0.08 0.02 0.08 0.08 0.01 0.02 0.22 0.04 0.01 0.17 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -2.79 0.60 -1.51 -6.23 -0.15 0.75 15 -0.74 -3.53 -4.46
Debt-free Net Working Capital (DFNWC)		 0.00 7.72 10 8.53 4.67 24 33 23 26 7.55 0.74
Net Working Capital (NWC)		 0.00 7.72 10 8.53 4.67 24 33 23 26 7.55 0.74
Net Nonoperating Expense (NNE)		 2.88 3.30 3.73 3.62 15 3.67 6.21 4.43 3.10 4.91 8.65
Net Nonoperating Obligations (NNO)		 0.00 -11 -9.41 -10 -11 -24 -34 -9.36 -26 -11 -5.20
Total Depreciation and Amortization (D&A)		 0.13 0.00 0.07 0.08 0.37 0.35 0.35 0.29 0.06 0.09 0.07
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.14) ($1.06) ($1.50) ($0.56) ($0.49) ($0.43) ($0.41) ($0.28) ($0.30)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 13.94M 16.02M 22.14M 40.34M 53.51M 58.03M 67.62M 76.48M 95.86M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.14) ($1.06) ($1.50) ($0.56) ($0.49) ($0.43) ($0.41) ($0.28) ($0.30)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 13.94M 16.02M 22.14M 40.34M 53.51M 58.03M 67.62M 76.48M 95.86M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($1.14) ($1.06) ($1.50) ($0.56) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 14.93M 17.40M 32.20M 92.33M 55.04M 61.33M 74.42M 80.02M 116.13M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.04 -7.97 -8.68 -8.86 -11 -14 -14 -14 -18 -18 -20
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 31.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Oncolytics Biotech

This table displays calculated financial ratios and metrics derived from Oncolytics Biotech's official financial filings.

Metric Q1 2025 Q1 2026
Period end date 3/31/2025 3/31/2026
DEI Shares Outstanding		 80,020,131.00 116,128,162.00
DEI Adjusted Shares Outstanding		 80,020,131.00 116,128,162.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.06 -0.08
Growth Metrics		 - -
Revenue Growth		 0.00% 0.00%
EBITDA Growth		 0.00% -92.78%
EBIT Growth		 0.00% -92.36%
NOPAT Growth		 0.00% -84.84%
Net Income Growth		 0.00% -96.20%
EPS Growth		 0.00% -33.33%
Operating Cash Flow Growth		 0.00% -54.09%
Free Cash Flow Firm Growth		 0.00% 0.00%
Invested Capital Growth		 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00%
Profitability Metrics		 - -
Gross Margin		 0.00% 0.00%
EBITDA Margin		 0.00% 0.00%
Operating Margin		 0.00% 0.00%
EBIT Margin		 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00%
Interest Burden Percent		 97.58% 99.53%
Effective Tax Rate		 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00%
Return on Equity (ROE)		 0.00% 648.95%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 648.95%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.51 -6.50
NOPAT Margin		 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -99.99%
Return On Investment Capital (ROIC_SIMPLE)		 - 126.64%
Cost of Revenue to Revenue		 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00%
R&D to Revenue		 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.83 -9.29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.81 -9.27
Valuation Ratios		 - -
Price to Book Value (P/BV)		 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00
Dividend Yield		 0.00% 0.00%
Earnings Yield		 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00
Leverage & Solvency		 - -
Debt to Equity		 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00
Financial Leverage		 0.00 1.07
Leverage Ratio		 0.00 -1.59
Compound Leverage Factor		 0.00 -1.58
Debt to Total Capital		 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00%
Debt to EBITDA		 0.00 0.00
Net Debt to EBITDA		 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00
Debt to NOPAT		 0.00 0.00
Net Debt to NOPAT		 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00
Altman Z-Score		 0.00 -74.27
Noncontrolling Interest Sharing Ratio		 0.00% 0.00%
Liquidity Ratios		 - -
Current Ratio		 0.00 1.38
Quick Ratio		 0.00 1.19
Cash Flow Metrics		 - -
Free Cash Flow to Firm (FCFF)		 0.00 4.13
Operating Cash Flow to CapEx		 -473,300.00% -121,550.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00
Efficiency Ratios		 - -
Asset Turnover		 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00
Inventory Turnover		 0.00 0.00
Fixed Asset Turnover		 0.00 0.00
Accounts Payable Turnover		 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00
Capital & Investment Metrics		 - -
Invested Capital		 0.00 -11
Invested Capital Turnover		 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -11
Enterprise Value (EV)		 0.00 93
Market Capitalization		 44 99
Book Value per Share		 $0.00 ($0.04)
Tangible Book Value per Share		 $0.00 ($0.04)
Total Capital		 0.00 -5.13
Total Debt		 0.00 0.00
Total Long-Term Debt		 0.00 0.00
Net Debt		 0.00 -5.49
Capital Expenditures (CapEx)		 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -3.43
Debt-free Net Working Capital (DFNWC)		 0.00 2.06
Net Working Capital (NWC)		 0.00 2.06
Net Nonoperating Expense (NNE)		 1.20 2.75
Net Nonoperating Obligations (NNO)		 0.00 -5.49
Total Depreciation and Amortization (D&A)		 0.02 0.02
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00%
Earnings Adjustments		 - -
Adjusted Basic Earnings per Share		 $0.00 ($0.08)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 112.29M
Adjusted Diluted Earnings per Share		 $0.00 ($0.08)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 112.29M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 119.35M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.51 -6.50
Normalized NOPAT Margin		 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00%
Debt Service Ratios		 - -
EBIT to Interest Expense		 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00
Payout Ratios		 - -
Dividend Payout Ratio		 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00%

Financials Breakdown Chart

Oncolytics Biotech Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Oncolytics Biotech's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Oncolytics Biotech's net income appears to be on an upward trend, with a most recent value of -$28.76 million in 2025, rising from -$9.92 million in 2015. The previous period was -$22.79 million in 2024. See where experts think Oncolytics Biotech is headed by visiting Oncolytics Biotech's forecast page.

Oncolytics Biotech's total operating income in 2025 was -$28.73 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $28.73 million

Over the last 10 years, Oncolytics Biotech's total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Oncolytics Biotech's total liabilities were at $11.38 million at the end of 2025, a 12.4% increase from 2024, and a 275.9% increase since 2016.

In the past 9 years, Oncolytics Biotech's cash and equivalents has ranged from $5.20 million in 2025 to $32.29 million in 2021, and is currently $5.20 million as of their latest financial filing in 2025.

Over the last 10 years, Oncolytics Biotech's book value per share changed from 0.00 in 2015 to -0.05 in 2025, a change of -4.8%.


Related Companies

Financial statements for NASDAQ:ONCY last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...
Profits Run | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
The tiny chipmaker set to supply Musk 5 billion chips
SpaceX and xAI just completed a $1.25 trillion merger - and Musk may no longer need data centers from Microsof...
Brownstone Research | Sponsoredtc pixel
The market’s crashing? … There’s an app for that
During the Great Financial Crisis, one firm accurately predicted 464 of 465 bank failures before they happened...
Weiss Ratings | Sponsoredtc pixel